Kazuhiko Shibata
Takaoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.
Journal: Cancer science
Published: December 22, 2025
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.
Journal: Oncogene
Published: October 29, 2025
Exploration of factors associated with eGFR slope improvement before and after intensive treatment of patients with diabetic nephropathy at high risk of disease progression: a retrospective cohort study.
Journal: Journal of rural medicine : JRM
Published: May 30, 2025
Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.
Journal: Thoracic cancer
Published: February 28, 2025
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 28, 2025
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer.
Journal: Translational lung cancer research
Published: June 03, 2024
Discharge to home from a palliative care unit: impact on survival and factors associated with home death after the discharge: a cohort study.
Journal: BMC palliative care
Published: May 25, 2023
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Journal: JAMA network open
Published: May 02, 2023
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data.
Journal: JTO clinical and research reports
Published: August 11, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Journal: Therapeutic advances in medical oncology
Published: August 10, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Journal: Therapeutic advances in medical oncology
Published: April 07, 2022
Last Updated: 09/26/2026